Ishay Yuval, Kenig Ariel, Tsemach-Toren Tehila, Amer Radgonde, Rubin Limor, Hershkovitz Yoav, Kharouf Fadi
Department of Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel; Gastroenterology Unit, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Department of Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Int Immunopharmacol. 2021 Oct;99:107970. doi: 10.1016/j.intimp.2021.107970. Epub 2021 Jul 10.
Vaccines represent an attractive possible solution to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Widespread vaccine distribution has yet to occur in most countries, partially due to public concerns regarding possible side effects. While studies indicate the vaccine is exceptionally safe, rare systemic side effects remain possible. In Israel, where a large percentage of the population has been rapidly vaccinated, such adverse events may be more apparent. We report a series of patients presenting with de-novo or flares of existing autoimmune conditions associated with the Pfizer BNT162b2 mRNA SARS-CoV-2 vaccine. All patients were assessed in our tertiary care center in Israel and had no history of previous SARS-COV-2 infection. We observed that while immune phenomena may occur following vaccination, they usually follow a mild course and require modest therapy. We briefly expound on the theoretical background of vaccine related autoimmunity and explore future research prospects.
疫苗是应对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行的一种颇具吸引力的可能解决方案。在大多数国家,广泛的疫苗分发尚未实现,部分原因是公众对可能的副作用存在担忧。虽然研究表明疫苗异常安全,但罕见的全身性副作用仍有可能发生。在以色列,很大一部分人口已迅速接种疫苗,此类不良事件可能更为明显。我们报告了一系列出现与辉瑞BNT162b2 mRNA SARS-CoV-2疫苗相关的新发或现有自身免疫性疾病发作的患者。所有患者均在以色列我们的三级医疗中心接受评估,且既往无SARS-CoV-2感染史。我们观察到,虽然接种疫苗后可能会出现免疫现象,但通常症状较轻,只需适度治疗。我们简要阐述了疫苗相关自身免疫的理论背景,并探讨了未来的研究前景。